Jim Simons Tyme Technologies, Inc. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

Shares

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 12, 2022	SELL	$0.23 - $0.35 $7,840 - $11,931	-34,090 Reduced 2.7%	1,226,721 $343,000
Q1 2022 May 13, 2022	BUY	$0.28 - $0.68 $249,046 - $604,828	889,453 Added 239.51%	1,260,811 $441,000
Q4 2021 Feb 11, 2022	SELL	$0.6 - $1.04 $109,885 - $190,467	-183,142 Reduced 33.03%	371,358 $224,000
Q3 2021 Nov 12, 2021	BUY	$0.99 - $1.38 $548,955 - $765,209	554,500 New	554,500 $571,000
Q3 2020 Nov 13, 2020	SELL	$0.93 - $1.35 $173,473 - $251,816	-186,531 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$0.97 - $1.7 $180,935 - $317,102	186,531 New	186,531 $248,000
Q1 2020 May 14, 2020	SELL	$0.9 - $1.95 $16,070 - $34,819	-17,856 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$1.0 - $1.49 $17,856 - $26,605	17,856 New	17,856 $25,000
Q3 2019 Nov 13, 2019	SELL	$0.97 - $1.77 $163,542 - $298,422	-168,600 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$0.96 - $1.89 $161,856 - $318,654	168,600 New	168,600 $206,000

About TYME TECHNOLOGIES, INC.

Ticker TYME
Exchange NASDAQ
Shares Outstandng 172,207,008
Description
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...

More about TYME

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.